Wellington Management Group LLP Has $1.15 Million Stock Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Wellington Management Group LLP cut its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 67.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,123 shares of the company’s stock after selling 478,277 shares during the period. Wellington Management Group LLP owned approximately 0.54% of Kyverna Therapeutics worth $1,150,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC acquired a new position in shares of Kyverna Therapeutics during the 3rd quarter worth about $33,000. Creative Planning bought a new position in Kyverna Therapeutics during the 3rd quarter worth approximately $54,000. Jacobs Levy Equity Management Inc. bought a new stake in Kyverna Therapeutics in the third quarter valued at approximately $97,000. Federated Hermes Inc. bought a new stake in Kyverna Therapeutics in the second quarter valued at approximately $120,000. Finally, BNP Paribas Financial Markets raised its holdings in Kyverna Therapeutics by 2,166.4% in the third quarter. BNP Paribas Financial Markets now owns 27,197 shares of the company’s stock worth $133,000 after purchasing an additional 25,997 shares during the period. Institutional investors own 18.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on KYTX. UBS Group assumed coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective for the company. Wells Fargo & Company decreased their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. HC Wainwright reduced their target price on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Finally, Rodman & Renshaw assumed coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $25.71.

Kyverna Therapeutics Stock Up 2.1 %

NASDAQ KYTX opened at $3.87 on Friday. The firm’s fifty day moving average price is $4.96 and its two-hundred day moving average price is $6.96. Kyverna Therapeutics, Inc. has a 1 year low of $3.63 and a 1 year high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter. On average, analysts anticipate that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.